Colorectal Cancer

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Increases in CRC screening were higher in high socioeconomic status and metropolitan areas, according to a new large cohort study.

Cologuard Plus bests its previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.

Having a PCP is linked to higher rates of screening colonoscopy and improved overall survival. Review these 12 facts about CRC and share them with your patients.

Your daily dose of the clinical news you may have missed.

Regular aspirin use was associated with a greater absolute reduction in CRC incidence among adults with unhealthier lifestyles, according to recent research.

Your daily dose of the clinical news you may have missed.

The Shield blood test is approved for primary CRC screening in adults 45 years and older at average risk for the disease.

Your daily dose of the clinical news you may have missed.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.

DDW 24. Among patients aged 15 to 19 years, the incidence of CRC rose 333% over a 22-year period, researchers reported.

Your daily dose of the clinical news you may have missed.

In average-risk individuals, the at-home ColoSense test demonstrated 93% sensitivity for detecting CRC and 45% sensitivity for detecting advanced adenomas.

New research suggests the interval "could potentially be extended" without significant harms and could reduce unnecessary invasive procedures. , ie, missed early detection and CRC-specific mortality.

The quality performance measure is viable and reliable and could help improve early CRC detection rates via timely colonoscopy following abnormal stool-based test.

Your daily dose of the clinical news you may have missed.

Cologuard Plus bests previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.

Findings from the ECLIPSE clinical trial showed the blood-based cancer screening test detects 83% of people with CRC, with a specificity of 90%.

Over 4 million cancer deaths have been reverted since 1991, but new cancer cases are estimated to reach over 2 million, according to new data from an annual American Cancer Society report.

Data from recent Austrian study suggest that sex should be considered when determining screening age for colorectal cancer, reported authors.

Your daily dose of the clinical news you may have missed.

A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.

The American College of Physicians in the updated guidance maintains the risk/benefit ratio supports screening initiation at age 50 (vs 45) years.